EP2421535A1 - Heteroaromatische und aromatische piperazinyl-azetidinyl-amide als monoacylglycerol-lipase-inhibitoren - Google Patents

Heteroaromatische und aromatische piperazinyl-azetidinyl-amide als monoacylglycerol-lipase-inhibitoren

Info

Publication number
EP2421535A1
EP2421535A1 EP10714829A EP10714829A EP2421535A1 EP 2421535 A1 EP2421535 A1 EP 2421535A1 EP 10714829 A EP10714829 A EP 10714829A EP 10714829 A EP10714829 A EP 10714829A EP 2421535 A1 EP2421535 A1 EP 2421535A1
Authority
EP
European Patent Office
Prior art keywords
compound
isobutyl
iss
cyclohexylmethyl
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10714829A
Other languages
English (en)
French (fr)
Inventor
Christopher M. Flores
Marina I. Nelen
Erica L. Nulton
Stephen Prouty
Matthew Todd
Sui-Po Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP2421535A1 publication Critical patent/EP2421535A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
EP10714829A 2009-04-22 2010-04-22 Heteroaromatische und aromatische piperazinyl-azetidinyl-amide als monoacylglycerol-lipase-inhibitoren Withdrawn EP2421535A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17166109P 2009-04-22 2009-04-22
PCT/US2010/032100 WO2010124122A1 (en) 2009-04-22 2010-04-22 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors

Publications (1)

Publication Number Publication Date
EP2421535A1 true EP2421535A1 (de) 2012-02-29

Family

ID=42226535

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10714829A Withdrawn EP2421535A1 (de) 2009-04-22 2010-04-22 Heteroaromatische und aromatische piperazinyl-azetidinyl-amide als monoacylglycerol-lipase-inhibitoren

Country Status (11)

Country Link
EP (1) EP2421535A1 (de)
JP (1) JP2012524810A (de)
KR (1) KR20120005517A (de)
CN (1) CN102458407B (de)
AU (1) AU2010238746B2 (de)
BR (1) BRPI1014874A2 (de)
CA (1) CA2759706A1 (de)
IL (1) IL215797A0 (de)
RU (1) RU2011147201A (de)
TW (1) TW201103914A (de)
WO (1) WO2010124122A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2760450A1 (de) * 2011-09-30 2014-08-06 Janssen Pharmaceutica, N.V. Monoacylglycerollipasehemmer zur behandlung von stoffwechselkrankheiten und verwandten erkrankungen
EP2935294A4 (de) 2012-12-21 2016-08-31 Univ California Verfahren und zusammensetzungen zur behandlung von cyanid- und schwefelwasserstofftoxizität
JP6454349B2 (ja) * 2013-12-26 2019-01-16 武田薬品工業株式会社 モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤としての４−（ピペラジン−１−イル）−ピロリジン−２−オン化合物
WO2016158956A1 (ja) * 2015-03-30 2016-10-06 武田薬品工業株式会社 複素環化合物
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
BR112018068538B1 (pt) 2016-03-31 2023-12-12 Takeda Pharmaceutical Company Limited Composto, medicamento, e, uso de um composto
WO2017170830A1 (ja) 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
MX2020007318A (es) 2017-09-29 2020-08-24 Takeda Pharmaceuticals Co Compuesto heterociclico.
EP3717477B1 (de) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG Neue heterocyclische verbindungen
TW201930300A (zh) * 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
EP3856178A1 (de) * 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerin-lipase-modulatoren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2915199B1 (fr) * 2007-04-18 2010-01-22 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
EP2180048B1 (de) * 2008-10-09 2014-12-17 Janssen Pharmaceutica N.V. Alternative Kristallform von Monoacylglycerinlipase (MGLL)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010124122A1 *

Also Published As

Publication number Publication date
CN102458407B (zh) 2014-03-05
KR20120005517A (ko) 2012-01-16
AU2010238746B2 (en) 2015-02-19
WO2010124122A1 (en) 2010-10-28
CN102458407A (zh) 2012-05-16
IL215797A0 (en) 2012-01-31
JP2012524810A (ja) 2012-10-18
BRPI1014874A2 (pt) 2016-04-12
CA2759706A1 (en) 2010-10-28
RU2011147201A (ru) 2013-05-27
AU2010238746A1 (en) 2011-11-10
TW201103914A (en) 2011-02-01

Similar Documents

Publication Publication Date Title
US8729064B2 (en) Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
AU2010238746B2 (en) Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
EP2611774B1 (de) Di-azetidinyl-diamid als monoacylglycerollipasehemmer
US8637498B2 (en) Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors
US8748417B2 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
WO2012054716A1 (en) Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
EP2421852B9 (de) Heteroaromatische und aromatische piperazinylazetidinylamide als monoacylglycerinlipaseinhibitor
US8513423B2 (en) Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA ME RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FLORES, CHRISTOPHER, M.

Inventor name: NELEN, MARINA, I.

Inventor name: NULTON, ERICA, L.

Inventor name: PROUTY, STEPHEN

Inventor name: TODD, MATTHEW

Inventor name: ZHANG, SUI-PO

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160818